Heimstaden AB
27.3.2026 12:21:30 CET | Globenewswire | Press release
Heimstaden 2026 Annual General Meeting
Heimstaden 2026 Annual General Meeting
Heimstaden AB has today held its Annual General Meeting 2026 and resolved the following:
- Adoption of the financial statements for the year ending 31 December 2025
- Adoption of the proposal for allocation of the Company’s results and payment of no dividends.
- Granted discharge from liability to the current Board Members, and the co-CEOs, for their management in 2025.
- Re-election of Ivar Tollefsen, John Giverholt, Bente Landsnes, and Fredrik Reinfeldt as Board Members.
- Adoption of the proposal for directors’ fees.
- Re-election of the registered auditing firm Ernst & Young Aktiebolag as external auditor, with Jonas Svensson as the auditor in charge.
Contact
Frederik Stentoft Berling, Media Relations, media@heimstaden.com
Cody Nelson, Investor Relations, +47 948 94 196, ir@heimstaden.com
About
Heimstaden is a leading European residential real estate manager and investor with around 158,000 homes across nine countries with a fair value of SEK 324 billion. We acquire, develop, and manage properties with an evergreen perspective. Heimstaden is listed on Nasdaq First North Growth Market. Read more at www.heimstadenab.com. Certified Adviser is DNB Carnegie Investment Bank AB.
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Holafly27.3.2026 13:56:09 CET | Press release
Earth Month 2026: 42% of travelers say they take steps to travel more responsibly, according to Holafly
Nykredit Realkredit A/S27.3.2026 13:54:38 CET | Press release
Correction: Announcement of drawings (CK95) - Nykredit Realkredit A/S
Nykredit Realkredit A/S27.3.2026 13:54:38 CET | Pressemeddelelse
Correction: Udtrækningsmeddelelse (CK95) - Nykredit Realkredit A/S
Royal UNIBREW A/S27.3.2026 13:03:03 CET | Press release
Notice to convene the Annual General Meeting in Royal Unibrew A/S
Sanofi Winthrop Industrie27.3.2026 13:00:00 CET | Press release
Press Release: Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom